Reassortant btv and ahsv vaccines
AssigneesThe University Court of the University of Glasgow, Merial Limited
InventorsMassimo Palmarini, Sandro Filipe Nunes, Pascal Hudelet, Jean Christophe Audonnet
Life of this patent
Estimating the term…
Abstract
The present invention encompasses BTV and ASHV vaccines or compositions and methods of producing recombinant reassortant BTV and ASHV vectors and methods of vaccination against BTV and ASHV.
Claims31
A composition or vaccine comprising one or more recombinant BTV or AHSV vectors comprising one or more heterologous polynucleotides encoding at least one polypeptides of BTV or AHSV, wherein the recombinant BTV or AHSV vectors comprise the vector backbones derived from the genomes selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26 of BTV or AHSV.
A recombinant BTV or AHSV vector comprising one or more heterologous polynucleotides encoding at least one polypeptides of BTV or AHSV, wherein the recombinant BTV or AHSV vectors comprise the vector backbones comprising the genomes selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26 of BTV or AHSV.
A method of producing a recombinant BTV or AHSV vector comprising transfecting a cell with:
- a) RNAs encoding one or more polypeptides of a serotype of BTV or AHSV;
- and
- b) RNAs comprising the transcripts of the entire genome of a serotype of BTV or AHSV that is different from the serotype of BTV or ASHV in a) and comprises the deletion of the transcripts encoding the polypeptides in a).
Dependencies are inferred from the claim text.